Do you clearly know the difference between strategies and tactics? How do you know if your strategy is a good one? Join WIB-Greater Boston for a panel discussion on strategy and how best to use it to reach your business objectives and career goals. We expect to have an interactive discussion of a nebulous and oft-confused topic, so bring your best thinking for a lively conversation.
5:30 p.m. - 6:10 p.m. Registration, Networking and Reception
6:15 p.m. - 7:15 p.m. Panel Discussion
7:15 p.m – 8: 00 p.m Networking
Diana Gallagher, M.D.
VP External Innovation and New Indications
Diana Gallagher leads the External Innovation and New Indications group at Biogen with a dual role in R&D and Corporate Development. Her group has core competencies in external innovation including search and evaluation but is augmented with preclinical research and clinical development capabilities. This enables her group to seek, evaluate and source new assets, then incubate new indications. In her almost 5 years at Biogen, she worked across discovery and clinical development with a focus on new and emerging areas for Biogen including Ophthalmology, Immunology, and others. She was an R&D leader for the recent acquisition of Nightstar Therapeutics, an ocular gene therapy company.
Prior to Biogen, Diana worked in Early Clinical Development at Merck on oral, IV, and inhaled products across a range of clinical indications. Before working in the industry she completed an MD at Johns Hopkins, a Masters in Medical Sciences at Harvard Medical School, along with an Internal Medicine residency and Pulmonary and Critical Care fellowship at the Harvard hospitals. In addition to the clinical time as an ICU physician, Diana was involved in research that was focused on endothelial barrier dysfunction.
Philina Lee, Ph.D.
VP Marketing, Patient Services and US Precision Medicine
Philina Lee, Ph.D., is Vice President, Marketing, Patient Services and US Precision Medicine at Blueprint Medicines, a precision therapy company developing a pipeline focused on genomically defined cancers, rare diseases and cancer immunotherapy. In 2014, she joined as the first employee focused on new product planning and strategy at Blueprint Medicines. She is currently focused on preparing for avapritinib’s potential product launch following NDA filing in June and MAA validation in July 2019, and pralsetinib’s potential product launch. She brings a deep passion for precision medicine and more than 10 years of experience in the biopharmaceutical industry, including U.S. and global oncology product launches, new product planning and portfolio strategy. Prior to joining Blueprint Medicines, she was the Xofigo® brand lead at Algeta, where she was the second commercial hire and contributed to building the company’s U.S. commercial organization and driving the successful launch of a novel targeted alpha-pharmaceutical for patients with castration-resistant prostate cancer. Previously, she held global and U.S. oncology marketing roles at Sanofi and Genzyme Oncology, and healthcare strategy consulting roles at Health Advances and Decision Resources Group providing strategic insights to biopharmaceutical and diagnostics clients. She holds a Ph.D. in Cell Biology from the Massachusetts Institute of Technology and a B.S. in Biochemistry from the University of Alberta.
Jennifer S. Chadwick, Ph.D.
BioAnalytix, Inc., Vice President, Biologics Development; Boston Chapter WIB Co-chair Mentors, Advisors, Peers and Sponsorship Program
Until November 15, 2019
- Members: $20
- Non-Members/Free Unlimited Guest Members*: $50
Beginning November 16, 2019
- Members: $30
- Non-Members/Free Unlimited Guest Members*: $60
*To access the Member rate, click here to purchase a WIB membership.
* - Walk-ins will be accepted until event capacity is reached.
Metered parking and garages in the area.
Directions from Public Transit
T Stop: Red Line, Kendal/MIT Stop